MAESTrO: PHARMAC proposal to retain first-line biologic access for adalimumab in dermatology and rheumatology indications

Posted by Michael Wonder on 29 Oct 2015

PHARMAC proposal to retain first-line biologic access for adalimumab in dermatology and rheumatology indications

29 October 2015 - PHARMAC is seeking feedback on a provisional agreement with AbbVie Limited to reduce the price and subsidy of adalimumab (Humira and HumiraPen) and to retain the same funded access criteria that currently apply to adalimumab.

For more details, go to: http://www.pharmac.health.nz/news/consultation-2015-10-29-adalimumab-access/

Posted by:

Michael Wonder

Posted in:

Medicine , Proposal , New Zealand , Market access